CN1074615A - 短舌匹菊的药用有效成分、其萃取方法和含有该药用有效成分的药剂 - Google Patents
短舌匹菊的药用有效成分、其萃取方法和含有该药用有效成分的药剂 Download PDFInfo
- Publication number
- CN1074615A CN1074615A CN93100855A CN93100855A CN1074615A CN 1074615 A CN1074615 A CN 1074615A CN 93100855 A CN93100855 A CN 93100855A CN 93100855 A CN93100855 A CN 93100855A CN 1074615 A CN1074615 A CN 1074615A
- Authority
- CN
- China
- Prior art keywords
- medicinal components
- effective medicinal
- levigated
- extract
- parthenii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000628997 Flos Species 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 28
- 239000003814 drug Substances 0.000 title claims description 18
- 239000000284 extract Substances 0.000 claims abstract description 42
- 238000000605 extraction Methods 0.000 claims abstract description 29
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 claims description 19
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 claims description 19
- 229940069510 parthenolide Drugs 0.000 claims description 19
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 13
- 229930009674 sesquiterpene lactone Natural products 0.000 claims description 13
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- PLSSEPIRACGCBO-PFFFPCNUSA-N santamarin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(C)=CC[C@@H](O)[C@@]21C PLSSEPIRACGCBO-PFFFPCNUSA-N 0.000 claims description 2
- PLSSEPIRACGCBO-UHFFFAOYSA-N santamarine Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC(O)C21C PLSSEPIRACGCBO-UHFFFAOYSA-N 0.000 claims description 2
- 230000008676 import Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract 2
- 241000196324 Embryophyta Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003921 oil Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 240000007817 Olea europaea Species 0.000 description 2
- 241001495453 Parthenium argentatum Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- -1 guayule lactone Chemical class 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- FKBUODICGDOIGB-PFFFPCNUSA-N reynosin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=C)CC[C@@H](O)[C@@]21C FKBUODICGDOIGB-PFFFPCNUSA-N 0.000 description 2
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FKBUODICGDOIGB-UHFFFAOYSA-N (+)-reynosin Natural products C1CC2C(=C)C(=O)OC2C2C(=C)CCC(O)C21C FKBUODICGDOIGB-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001495454 Parthenium Species 0.000 description 1
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N Parthenium Chemical compound C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930008578 reynosin Natural products 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Extraction Or Liquid Replacement (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
Abstract
由含有多种成分的混合物、特别是由粉碎的植物
如短舌匹菊中用超临界状态的气体最好是CO2萃取
药用有效成分，萃取物收率高，有效成分的稳定性意
外地得到了改善。
Description
本发明涉及由具有倍半萜-内酯的银胶菊内酯及其类似化合物作为可控含量的短舌匹菊得到的药用有效成分。本发明还涉及由磨细的短舌匹菊萃取药用有效成份的方法，以及用得到的药用有效成份制备药剂。
在EP0098041A1中叙述了由粉碎的短舌匹菊植物制备萃取物的方法，即用一种油从该植物中萃取倍半萜-内酯，由此植物获取倍半萜-内酯通常可考虑用非极性有机溶剂，如石油醚、己烷或氯仿，为此可用第一个非极性溶剂萃取后蒸发掉，然后用第二个非极性溶剂作为洗脱剂进行层析。
在“小白菊的有效成份”（Lancet，Vol7，1981年11月，1054页）论文中报导了用石油醚从干燥的植物中制备萃取物，然后用苯作为非极性洗脱剂进行层析。在“生化系统学与生态学”1977，207～218页中叙述了用氯仿作为非极性萃取剂，由短舌匹菊中萃取倍半萜-内酯。
已知还可用磷酸缓冲液进行萃取。
已知的萃取方法显示了较低的收率，此外，由短舌匹菊萃取的倍半萜-内酯也不太稳定。
本发明内容是提供了由短舌匹菊萃取新的具有较高稳定性的药用
有效成分或药剂。
按照本发明由短舌匹菊制得的以倍半萜-内酯银胶菊内酯作为可控制含量的物质药用有效成分，是按如下操作步骤得到的，
＊将植物磨细
＊在温度为32℃～60℃，压力为150～350巴的超临界态的条件下，用C02进行萃取。
本发明的由短舌匹菊得到的药用有效成分与迄今所用的萃取方法所得到的萃取物是不同的。区别在于本发明成分的银胶菊内酯含量存放时间超过一年时基本上不变，而常规的萃取物中银胶菊内酯的含量在此期间会降低。由短舌匹菊得到的本发明的药用有效成分与常规的萃取物的区别主要是，用常规方法，倍半萜-内酯的所特有的活性基团会破坏，如环外亚甲基，和环氧基，而本发明成分中的这些物质则不会变。
上述的内容可用开始时提及的技术加以解决，即在温度为32℃～60℃、压力为150～350巴的超临界状态的条件下用C02进行萃取。
这个方法对上述药用有效成分有出人意料的优点。
用本发明方法得到的萃取物，其优点是不残留溶剂，因而最后不会含有不能挥发的污染性物质。
用超临界态的CO2萃取法可将生药中成分彻底萃取出，而用其它溶剂则达不到。
萃取最好是在32℃-60℃温度之间进行，优选的压力范围是150～350巴，参数的优选组合为60℃和300～350巴或40℃时200巴。
彻底萃取是这样进行的：在超临界态的CO2循环地被导入到粉碎的植物中，工业规模是用超临界状态的气体处理大约3小时。
用超临界态的CO2萃取短舌匹菊，得到富含倍半萜-内酯特别是银胶菊内脂的稳定的萃取物，根据选择的萃取条件之不同，萃取收率在90～99%，银胶菊内脂的相应收率为11.9～14.4%。
本发明制取的萃取物可用于制备药剂，该药剂特别适于治疗偏头疼，哮喘，气管炎或关节炎。
令人奇怪的是，在亲脂性萃取物中可含有大约5%的残留水分，因而植物来源的极性物质会混入萃取物中，含有的极性物质以及萜类和叶绿素，在制成药物制剂软胶囊时，会与明胶的氨基反应，生成横向交叉连接，这就阻止了明胶壳的迅速崩解，负责横向交叉连接的内容物在明胶壳破壳后虽然不再是胶囊的内容物，而是完全与胶囊壳结合在一起，这种不希望的效果可通过向要萃取的生药中加入硅胶来避免最好是每公斤磨细的植物（生药）中加入60～140g硅胶，用硅胶处理会使萃取的收率降低，优选用100克。
有效的倍半萜-内酯银胶菊内酯，Santamarin和reynosin也可由短舌匹菊中分步萃取出。经过这种分步萃取得到的萃取物，它可以油性制剂用于软明胶胶囊中，并且没有横向交叉连接。
用压缩性气体进行萃取原则上是已知的方法，这种萃取方法的原理和主要应用范围的评述可见Peter Brunner所著“用压缩气萃取的现状”（见Chem，-Ing、-Tech，53卷，1981年，529～542页）。除介绍了用超临界态的气体进行萃取的原理外还用表列出了应用实例，主要应用范围是用气体萃取石油和类似制品，煤炭，橄榄油和脂肪，以及从咖啡中除去咖啡因。还提及了制备
药物的独特的未进一步说明的应用情况。
在Schmist List的著作“植物药制造的工艺学”（斯图加特，1984，159～173页）也叙述了用超临界态的气体进行萃取的方法，优选的萃取用气体可提及CO2，列举了在制药领域中的一些应用，其主要优点是保障了萃取物中没有溶剂。用临界态的CO2萃取得到的另外的萃取物如同用常规的萃取方法那样，并且该萃取物显示出其它的性质，这提示该技术情况未被显示出。
用本发明萃取方法获得的药用有效成分含有作为控制含量的倍半萜-内酯银胶菊内酯。
用优选的操作条件得到的萃取物含有脂肪样物质，有强烈气味，并随着萃取时间的延长而变黑。萃取物最好是直接溶解或悬浮于一种常规药用油或油的组合物中。这种溶液特别适于加到软明胶胶囊中。当然其它的制剂也是可行的。
用所述的方法得到的萃取物在与用其它萃取方式进行药理实验的比较时，在抗炎和解痉性质方面显示了优良的结果。
萃取和萃取物的物理化学参数列于下表1中
试验 2 3
萃取参数 350巴/60℃ 200巴/40℃
颜色 深橄榄绿 橄榄绿
稠度 油脂样 油脂样
气味 特异芳香 特异芳香
熔点 44-47℃ 43-47℃
下面所述的实施例说明了工业规模获得萃取物的方法。
实施例1
在装有温度和压力控制的全部仪器的10l萃取器中放入3.2kg磨细的短舌匹菊生药。封闭好仪器后，由贮罐中引入超临界态的气态CO2，然后用泵连续地循环充气，这个过程反复循环于350巴和60℃为时3小时，直至生药彻底萃取。
萃取得量99.9g，银胶菊内酯得量11.4g;萃取物中银胶菊内酯含量11.4%;萃取后生药中残存银胶菊内酯含量0.9g。
实施例2
在装有温度和压力控制的全部仪器的10l萃取器中放入3.1kg磨细的短舌匹菊生药，封闭好仪器后，由贮罐中引入超临界态的气态CO2，然后用泵连续地循环充气，该过程在200巴和40℃下反复循环3小时，直到生药彻底被萃取。
萃取得量90.1g;银胶菊内酯得量11.9g;萃取物中银胶菊内酯含量为13.2%;萃取后生药中残存的银胶菊内酯为1.1g。
用超临界态CO2萃取，不仅可得到很高收率的萃取物，而且有效成份的稳定性也很高。下表列出的是将常规用的乙醇-水萃取物与本发明的CO2萃取物放置时间长达大约1.5年后银胶菊内酯含量的比较。
结果表明用乙醇-水萃取物中银胶菊内酯的百分含量有很大的降低，而用CO2萃取物银胶菊内酯的含量实际是不变的。
Claims (18)
1、用倍半萜-内酯银胶菊内酯及银胶菊内酯的类似化合物作为可控含量的短舌匹菊的药用有效成分，可用如下的操作步骤获得：
-将植物磨细
-用在温度为32°～60℃、压力为150～350巴的超临界态的CO2进行萃取。
2、按照权利要求1的药用有效成分，于温度为60℃、压力为300～350巴条件下经萃取方法获得。
3、按照权利要求1的药用有效成分，于温度为40℃，压力为200巴条件下，经萃取方法获得。
4、按照权利要求1到3的一项所述的药用有效成分，经向磨细的植物中加入硅胶附加操作步骤而获得。
5、按照权利要求4的药用有效成分，每公斤磨细的植物中经加入60～140g硅胶而获得。
6、按照权利要求5的药用有效成分，每公斤磨细的植物中经加入100g硅胶而获得。
7、按照权利要求1到3的一项所述的药用有效成分，由萃取物将倍半萜-内酯银胶菊内酯、Santamarin和Reyhosin分步分离而获得
8、由磨细的短舌匹菊萃取药用有效成分的方法，其特征是，在温度为32°～60℃、压力为150～350巴的条件下用超临界状态的CO2进行萃取。
9、按照权利要求4的方法，其特征是，该萃取过程是在温度为60℃、压力为300～350巴的条件下进行。
10、按照权利要求4的方法，其特征是，该萃取过程是在温度为40℃、压力为200巴的条件下进行。
11、按照权利要求4到6的一项所述的方法，其特征是，将超临界状态的CO2循环导入到磨细的短舌匹菊上。
12、按照权利要求7的方法，其特征是，超临界状态的CO2的循环处理直到彻底萃取为止。
13、按照权利要求7到11中的一项所述的方法，其特征是，在用CO2萃取之前，向磨细的短舌匹菊中加入硅胶。
14、按照权利要求12的方法，其特征是，每kg磨细的植物中加入60～140g硅胶。
15、按照权利要求13的方法，其特征是，每kg磨细的植物中加入100g硅胶。
16、按照权利要求8到15一项所述的方法，其特征是，将获得的萃取物分步分离得到倍半萜-内酯银胶菊内酯、Sartmarin和reynusin。
17、含有按照权利要求7到14中的一项的方法获得的药用有效成分的药剂，将其溶解或悬浮在药用油中。
18、按照权利要求16或15和16的药剂，其特征是，以软明胶胶囊的形式给药。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4202657A DE4202657C2 (de) | 1992-01-31 | 1992-01-31 | Pharmazeutisch wirksame Zusammensetzung aus Tanacetum parthenium sowie Verfahren zu deren Extraktion und mit der pharmazeutisch wirksamen Zusammensetzung hergestelltes Arzneimittel |
| DEP4202657.1 | 1992-01-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1074615A true CN1074615A (zh) | 1993-07-28 |
| CN1074927C CN1074927C (zh) | 2001-11-21 |
Family
ID=6450610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100855A Expired - Fee Related CN1074927C (zh) | 1992-01-31 | 1993-01-30 | 短舌匹菊的药用有效成份其萃取方法和含有该药用有效成分的药剂 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5466451A (zh) |
| EP (1) | EP0553658B2 (zh) |
| JP (1) | JP3611869B2 (zh) |
| CN (1) | CN1074927C (zh) |
| AT (1) | ATE150314T1 (zh) |
| BR (1) | BR9300361A (zh) |
| CA (1) | CA2088289C (zh) |
| CZ (1) | CZ286486B6 (zh) |
| DE (2) | DE4202657C2 (zh) |
| DK (1) | DK0553658T4 (zh) |
| EG (1) | EG20104A (zh) |
| ES (1) | ES2099296T5 (zh) |
| GR (1) | GR3023202T3 (zh) |
| HU (1) | HUT64232A (zh) |
| MX (1) | MX9300265A (zh) |
| PL (1) | PL171097B1 (zh) |
| RU (1) | RU2104017C1 (zh) |
| SK (1) | SK279652B6 (zh) |
| UA (1) | UA26917C2 (zh) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2695931B1 (fr) * | 1992-09-24 | 1994-10-28 | Madeca | Procédé pour l'obtention de lactone sesquiterpénique de parthénolide, et préparation thérapeutique contenant un tel produit pour le traitement de la migraine. |
| WO1999033463A1 (en) * | 1997-12-23 | 1999-07-08 | Moser, René | SESQUITERPENE LACTONES SPECIFICALLY INHIBIT ACTIVATION OF NF-λB BY PREVENTING THE DEGRADATION OF IλB-α AND IλB-$g(b) |
| DE19800330C2 (de) * | 1998-01-07 | 2002-09-26 | Delta 9 Pharma Gmbh | Pharmazeutisch wirksamer CO¶2¶-Extrakt aus Tanacetum parthenium |
| US6068999A (en) * | 1998-06-25 | 2000-05-30 | Hendrix; Curt | Dietary supplement for supporting cerebrovascular tone and treating migraine headaches |
| GB2340120B (en) * | 1998-08-01 | 2003-06-18 | Essential Nutrition Ltd | Nettle extract containing phytosterols |
| DE19844836A1 (de) | 1998-09-30 | 2000-04-20 | Hexal Ag | Pharmazeutisch, wirksames, pflanzliches Präparat zur Behandlung von Migräne |
| IT1312342B1 (it) * | 1999-06-03 | 2002-04-15 | Indena Spa | Estratto di tanacetum parthenium sostanzialmente privo di gammalattoni-alfa-insaturi. |
| US7192614B2 (en) | 2002-11-05 | 2007-03-20 | Gelstat Corporation | Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
| US20040219229A1 (en) * | 2003-04-30 | 2004-11-04 | Tim Clarot | Migraine relief composition and methods of using and forming same |
| CN1882354B (zh) * | 2003-09-12 | 2012-07-04 | 捷通国际有限公司 | 细胞因子调节剂及相关用法 |
| US7758903B2 (en) | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
| US7758902B2 (en) * | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
| US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
| DE102004037002B4 (de) * | 2004-07-30 | 2006-06-14 | Chemieanlagenbau Chemnitz Gmbh | Verfahren zur Herstellung von Dimethylaminoarglabin-Hydrochlorid |
| US20060222722A1 (en) * | 2005-03-30 | 2006-10-05 | Roberts Stephen C | Sublingual methods of treatment to alleviate or prevent arthritis |
| US8409637B2 (en) * | 2007-06-21 | 2013-04-02 | Puramed Bioscience Inc. | Compositions and methods for treating and preventing migrainous headaches and associated symptoms |
| CN103524520B (zh) * | 2013-09-25 | 2015-12-09 | 中国人民解放军第四军医大学 | 一种从植物原料中提取小白菊内酯的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3119454A1 (de) * | 1981-05-15 | 1982-12-09 | Haarmann & Reimer Gmbh, 3450 Holzminden | Verfahren zur herstellung von konzentrierten extrakten aus frischen pflanzen oder teilen davon, insbesondere frischen kuechenkraeutern |
| CA1270843A (en) * | 1982-05-19 | 1990-06-26 | Edward Stewart Johnson | Sesquiterpene lactones |
| GB8428747D0 (en) * | 1984-11-14 | 1984-12-27 | Hancock K A | Products for treatment of human body |
| FI73962C (fi) * | 1985-03-01 | 1987-12-10 | Yhtyneet Paperitehtaat Oy | Foerfarande foer framstaellning av vanillin. |
| FR2629735B1 (fr) * | 1988-04-11 | 1991-03-22 | Agronomique Inst Nat Rech | Procede d'extraction au dioxyde de carbone supercritique de composes volatils, et composes obtenus |
| US4996317A (en) * | 1988-08-05 | 1991-02-26 | Kraft General Foods, Inc. | Caffeine recovery from supercritical carbon dioxide |
| US5196575A (en) * | 1992-02-19 | 1993-03-23 | Hoechst Celanese Corp. | Supercritical separation of isomers of functional organic compounds at moderate conditions |
-
1992
- 1992-01-31 DE DE4202657A patent/DE4202657C2/de not_active Expired - Fee Related
-
1993
- 1993-01-12 HU HU9300069A patent/HUT64232A/hu unknown
- 1993-01-15 EP EP93100522A patent/EP0553658B2/de not_active Expired - Lifetime
- 1993-01-15 DE DE59305824T patent/DE59305824D1/de not_active Expired - Fee Related
- 1993-01-15 DK DK93100522T patent/DK0553658T4/da active
- 1993-01-15 AT AT93100522T patent/ATE150314T1/de not_active IP Right Cessation
- 1993-01-15 ES ES93100522T patent/ES2099296T5/es not_active Expired - Lifetime
- 1993-01-20 MX MX9300265A patent/MX9300265A/es unknown
- 1993-01-20 PL PL93297473A patent/PL171097B1/pl not_active IP Right Cessation
- 1993-01-26 EG EG5293A patent/EG20104A/xx active
- 1993-01-26 CZ CZ199382A patent/CZ286486B6/cs not_active IP Right Cessation
- 1993-01-26 JP JP01112493A patent/JP3611869B2/ja not_active Expired - Fee Related
- 1993-01-28 CA CA002088289A patent/CA2088289C/en not_active Expired - Fee Related
- 1993-01-28 BR BR9300361A patent/BR9300361A/pt not_active Application Discontinuation
- 1993-01-29 SK SK46-93A patent/SK279652B6/sk not_active IP Right Cessation
- 1993-01-29 RU RU93004547A patent/RU2104017C1/ru not_active IP Right Cessation
- 1993-01-29 US US08/011,526 patent/US5466451A/en not_active Expired - Lifetime
- 1993-01-30 CN CN93100855A patent/CN1074927C/zh not_active Expired - Fee Related
- 1993-05-12 UA UA93004405A patent/UA26917C2/uk unknown
-
1997
- 1997-04-21 GR GR970400863T patent/GR3023202T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2099296T3 (es) | 1997-05-16 |
| EP0553658A2 (de) | 1993-08-04 |
| HUT64232A (en) | 1993-12-28 |
| UA26917C2 (uk) | 1999-12-29 |
| EP0553658B2 (de) | 2007-02-14 |
| ES2099296T5 (es) | 2007-10-16 |
| DE59305824D1 (de) | 1997-04-24 |
| ATE150314T1 (de) | 1997-04-15 |
| BR9300361A (pt) | 1993-08-24 |
| CZ286486B6 (en) | 2000-04-12 |
| US5466451A (en) | 1995-11-14 |
| DK0553658T4 (da) | 2007-03-19 |
| EP0553658B1 (de) | 1997-03-19 |
| CA2088289A1 (en) | 1993-08-01 |
| EP0553658A3 (zh) | 1994-02-16 |
| PL297473A1 (en) | 1993-08-09 |
| DE4202657C2 (de) | 1995-10-12 |
| JP3611869B2 (ja) | 2005-01-19 |
| DK0553658T3 (da) | 1997-04-07 |
| HU9300069D0 (en) | 1993-04-28 |
| CA2088289C (en) | 2002-11-12 |
| MX9300265A (es) | 1993-11-01 |
| RU2104017C1 (ru) | 1998-02-10 |
| DE4202657A1 (de) | 1993-08-05 |
| CZ8293A3 (en) | 1993-12-15 |
| EG20104A (en) | 1997-07-31 |
| SK279652B6 (sk) | 1999-02-11 |
| GR3023202T3 (en) | 1997-07-30 |
| SK4693A3 (en) | 1993-09-09 |
| JPH0656683A (ja) | 1994-03-01 |
| PL171097B1 (pl) | 1997-03-28 |
| CN1074927C (zh) | 2001-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1074927C (zh) | 短舌匹菊的药用有效成份其萃取方法和含有该药用有效成分的药剂 | |
| JP5021879B2 (ja) | アボガドのフラン脂質化合物およびポリヒドロキシル化された脂肪族アルコールを抽出する方法、該化合物に基く組成物および治療、美容並びに食品における該化合物の使用 | |
| KR0133651B1 (ko) | 액체 항산화제 향료 추출물의 제조방법 | |
| US4218489A (en) | Antioxidants, antioxidant compositions and methods of preparing and using same | |
| HU196559B (en) | Process for production of capsules of big stability from mild gelatine for medical purpuses containing as active substance of oils of natural origin | |
| EP0250953A1 (en) | Process for the extraction of oily fruits | |
| WO2022101490A1 (en) | Eutectic compositions, methods and uses thereof | |
| JPH0617050A (ja) | 天然の植物性酸化防止剤の製造法 | |
| KR20010086168A (ko) | 지질 함유 대두 추출물, 이의 제조방법, 및 약제 및 화장조성물 | |
| KR100362923B1 (ko) | 초고순도의난유를수득하는방법및이것의용도 | |
| KR100609765B1 (ko) | 프로락틴 저하제 | |
| EP1222008B1 (fr) | Procede d'extraction par fluide supercritique | |
| US4649206A (en) | Lignan compound | |
| RU2777415C1 (ru) | Жидкий экстракт родиолы розовой, обладающий антиоксидантным действием, и способ его получения | |
| Kusumaningrum et al. | Effect of Solvent Type and Extraction Time on Binahong Leaf Extraction Process | |
| Rosa et al. | Evaluation of the Healing Properties of Pentaclethra Macrophylla Seed Pod on Diabetic Wounds | |
| RU2394587C1 (ru) | Средство, обладающее гипохолестеринимическим, гиполипидемическим и желчегонным действием | |
| RU2163133C1 (ru) | Способ полученя масляного экстракта чеснока | |
| AU2001242730B2 (en) | An Anti-Diabetic Agent obtained from the plant Humboldtia Decurrens and a Process for preparing the same | |
| JPS62223291A (ja) | 抗酸化性・抗菌性物質の製造法 | |
| Shiihara | Silanol-group addition reaction to active double bonds | |
| AU2001242730A1 (en) | An Anti-Diabetic Agent obtained from the plant Humboldtia Decurrens and a Process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20011121 Termination date: 20100130 |